Novel Biomarkers for Personalized Cancer Immunotherapy.

ABSTRACT: Cancer immunotherapy has emerged as a novel and effective treatment strategy for several types of cancer. Immune checkpoint inhibitors (ICIs) have recently demonstrated impressive clinical benefit in some advanced cancers. Nonetheless, in the majority of patients, the successful use of ICIs is limited by a low response rate, high treatment cost, and treatment-related toxicity. Therefore, it is necessary to identify predictive and prognostic biomarkers to select the patients who are most likely to benefit from, and respond well to, these therapies. In this review, we summarize the evidence for candidate biomarkers of response to cancer immunotherapy.

SUBMITTER: Shindo Y 

PROVIDER: S-EPMC6770350 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature